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Abstract
Background
Mass azithromycin distributions have been shown to reduce mortality in preschool children,
although the factors mediating this mortality reduction are not clear. This study was per-
formed to determine whether mass distribution of azithromycin, which has modest antima-
larial activity, reduces the community burden of malaria.
Methods and findings
In a cluster-randomized trial conducted from 23 November 2014 until 31 July 2017, 30 rural
communities in Niger were randomized to 2 years of biannual mass distributions of either
azithromycin (20 mg/kg oral suspension) or placebo to children aged 1 to 59 months. Partici-
pants, field staff, and investigators were masked to treatment allocation. The primary
malaria outcome was the community prevalence of parasitemia on thick blood smear,
assessed in a random sample of children from each community at study visits 12 and 24
months after randomization. Analyses were performed in an intention-to-treat fashion. At
the baseline visit, a total of 1,695 children were enumerated in the 15 azithromycin commu-
nities, and 3,029 children were enumerated in the 15 placebo communities. No communities
were lost to follow-up. The mean prevalence of malaria parasitemia at baseline was 8.9%
(95% CI 5.1%–15.7%; 52 of 552 children across all communities) in the azithromycin-
treated group and 6.7% (95% CI 4.0%–12.6%; 36 of 542 children across all communities) in
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the placebo-treated group. In the prespecified primary analysis, parasitemia was lower in
the azithromycin-treated group at month 12 (mean prevalence 8.8%, 95% CI 5.1%–14.3%;
51 of 551 children across all communities) and month 24 (mean 3.5%, 95% CI 1.9%–5.5%;
21 of 567 children across all communities) than it was in the placebo-treated group at month
12 (mean 15.3%, 95% CI 10.8%–20.6%; 81 of 548 children across all communities) and
month 24 (mean 4.8%, 95% CI 3.3%–6.4%; 28 of 592 children across all communities) (P =
0.02). Communities treated with azithromycin had approximately half the odds of parasite-
mia compared to those treated with placebo (odds ratio [OR] 0.54, 95% CI 0.30 to 0.97).
Parasite density was lower in the azithromycin group than the placebo group at 12 and 24
months (square root–transformed outcome; density estimates were 7,540 parasites/μl
lower [95% CI −350 to −12,550 parasites/μl; P = 0.02] at a mean parasite density of 17,000,
as was observed in the placebo arm). No significant difference in hemoglobin was observed
between the 2 treatment groups at 12 and 24 months (mean 0.34 g/dL higher in the azithro-
mycin arm, 95% CI −0.06 to 0.75 g/dL; P = 0.10). No serious adverse events were reported
in either group, and among children aged 1 to 5 months, the most commonly reported non-
serious adverse events (i.e., diarrhea, vomiting, and rash) were less common in the azithro-
mycin-treated communities. Limitations of the trial include the timing of the treatments and
monitoring visits, both of which took place before the peak malaria season, as well as the
uncertain generalizability to areas with different malaria transmission dynamics.
Conclusions
Mass azithromycin distributions were associated with a reduced prevalence of malaria para-
sitemia in this trial, suggesting one possible mechanism for the mortality benefit observed
with this intervention.
Trial registration
The trial was registered on ClinicalTrials.gov (NCT02048007).
Author summary
Why was this study done?
• The Macrolides Oraux pour Re´duire les De´ce´s avec un Oeil sur la Resistance (MOR-
DOR) trial found that distributing the antibiotic azithromycin to all preschool children
in communities in Niger was effective for preventing childhood mortality.
• It is unclear how azithromycin might prevent mortality, though this antibiotic has mod-
erate activity against malaria parasites.
What did the researchers do and find?
• Thirty communities from the same study area as MORDOR were randomized to receive
the same interventions: either mass distribution of azithromycin or mass distribution of
placebo to all children ages 1 to 59 months every 6 months over a 2-year period.
Mass azithromycin and malaria in Niger
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• A blood smear test for malaria was performed on a random sample of 40 children per
community before treatment and at 12 and 24 months after the initial distribution.
• Communities randomized to the antibiotic had fewer malaria parasites at months 12
and 24 than those randomized to placebo.
What do these findings mean?
• Mass azithromycin distributions may reduce the burden of malaria in Niger, which may
in turn contribute to the mortality benefit of this intervention.
• Future studies will be important to study how frequently to give treatment, the effective-
ness of azithromycin during various seasons of the year, and the generalizability of this
finding to other settings in sub-Saharan Africa.
Introduction
Mass azithromycin distributions have lowered childhood mortality in Africa, although the
mechanism explaining this effect is unknown. Macrolides Oraux pour Re´duire les De´ce´s avec
un Oeil sur la Resistance (MORDOR) was a cluster-randomized placebo-controlled trial con-
ducted in Malawi, Niger, and Tanzania that found a 14% reduction in childhood mortality in
communities randomized to biannual mass azithromycin distributions targeted to 1- to
59-month-old children. The protective effect of azithromycin distributions was especially high
in Niger, where malaria accounts for a large proportion of childhood deaths [1]. Azithromycin
has activity against the malarial apicoplast and has demonstrated modest antimalarial activity
in vitro and in numerous field studies [2–13]. Thus, the mortality benefit observed with mass
azithromycin distributions may be due, in part, to decreased malaria.
MORDOR was designed as a large simple trial the outcome of which was childhood mortal-
ity as assessed on biannual census. Detailed health assessments were not performed in MOR-
DOR in order to minimize co-interventions that could have biased the result of the trial.
Instead, additional communities drawn from the MORDOR study area were enrolled into a
parallel trial with the same interventions that also included annual monitoring visits to investi-
gate possible mechanisms by which azithromycin impacted mortality. The present report
details the results of blood smears processed for malaria in the parallel trial from Niger. Cluster
randomization was employed to account for both the direct effects of the antibiotic as well as
any indirect spillover effects of widespread community antibiotic use [14]. We hypothesized
that mass azithromycin distributions would reduce the community prevalence of malaria para-
sitemia relative to placebo.
Methods
Trial design
A parallel-group, cluster-randomized trial was performed in the Boboye and Loga departments
of Niger from 23 November 2014 to 31 July 2017 (Fig 1). Communities were randomly selected
from the same pool of communities as the main MORDOR trial in order to allow the findings
of this trial to be generalizable to the parent study population (Fig 2). A set of 30 communities
was randomized in a 1:1 ratio to biannual (i.e., every 6 months) mass treatment of preschool
Mass azithromycin and malaria in Niger
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children with a single dose of either azithromycin or placebo (i.e., the same interventions
offered in the main trial). Communities were followed annually with detailed morbidity assess-
ments, including blood smears. Ethical approval was obtained from the Committee on Human
Fig 1. Trial flow. Communities were selected from the same pool of communities as the parent MORDOR trial; communities were
excluded before randomization if not in the desired population range (i.e., 200–2,000 people) or if not required to reach the targeted
sample size. A census was conducted approximately every 6 months. A random sample of children was selected at months 0, 12, and
24 for monitoring. Children excluded from analysis had thick smears that were missing or unreadable. MORDOR, Macrolides
Oraux pour Re´duire les De´ce´s avec un Oeil sur la Resistance.
https://doi.org/10.1371/journal.pmed.1002835.g001
Mass azithromycin and malaria in Niger
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Research at the University of California, San Francisco and the Institutional Review Board of
the Nigerien Ministry of Health. The trial was reported according to Consolidated Standards
of Reporting Trials (CONSORT) guidelines (S1 Checklist). Details of the study design were
prespecified in a trial protocol (S1 Protocol).
Fig 2. MORDOR study area. MORDOR was conducted in Boboye and Loga departments, Dosso region, Niger. Each
point represents a community, with azithromycin-treated communities in blue and placebo-treated communities in
orange. The 30 communities enrolled in the present study (darker markers) were randomly selected from the same
pool of communities as the main MORDOR trial (lighter markers). Base maps of the Loga and Boboye departments
were taken from the Humanitarian Data Exchange (https://data.humdata.org). MORDOR, Macrolides Oraux pour
Re´duire les De´ce´s avec un Oeil sur la Resistance.
https://doi.org/10.1371/journal.pmed.1002835.g002
Mass azithromycin and malaria in Niger
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Participants
The unit of randomization for the trial was the grappe, a government-defined health catch-
ment area, termed “community” in this report. Communities with a population between 200
and 2,000 on the most recent government census were eligible. No mass azithromycin distri-
butions for trachoma had been administered in the study area for the previous 5 years, and no
seasonal malaria chemoprevention programs were implemented during the study period. All
children aged 1 to 59 months of age who weighed 3,800 g or more were eligible for treatment.
A random selection of 40 children aged 1 to 59 months per community was invited to provide
a finger-stick blood specimen for thick and thin smear. Guardians of children provided oral
informed consent for both treatment and monitoring.
Randomization and masking
Communities were randomly assigned in equal proportions to 1 of 6 letters by the trial biostat-
istician with the statistical package R (R Foundation for Statistical Computing, Vienna, Aus-
tria). The Nigerien study coordinator then enrolled communities and assigned the allocated
intervention. Allocation was concealed at the cluster level by enrolling all communities before
randomization and at the individual level by administering the treatment to all eligible chil-
dren. Bottles of study drug were labelled by the manufacturer (Pfizer, New York, NY) with one
of the 6 treatment letters, with 3 letters corresponding to azithromycin and 3 letters to placebo.
Study bottles, packaging, and the appearance of the drug were identical. Participants, field per-
sonnel, laboratory staff, and all investigators except the trial biostatistician were masked to
treatment allocation.
Census
All households in each community were enumerated approximately every 6 months over a
2.5-year period using similar methods as the main trial [1]. All children aged�12 years in the
household were documented.
Monitoring
A monitoring visit was performed during the first census period before distribution of the
study drug (median date 26 March 2015) and then approximately 12 and 24 months later
(median dates 23 June 2016 and 25 April 2017, respectively). The monitoring visits at months
12 and 24 occurred before distribution of study medication for the respective study period, as
well as approximately 6 months after the treatment from the previous phase. Thus, the
12-month visit was performed approximately 6 months after the second round of mass treat-
ment, and the 24-month visit was performed approximately 6 months after the fourth round
of treatment (Fig 3). As part of the assessments, each child had a finger stick performed, with
hemoglobin measurements estimated with a Hemocue Hb 201+ device (A¨ngelholm, Sweden)
and malaria parasitemia assessed via thick and thin smear applied to a single slide. Slides were
labelled with a random number sticker to mask the laboratory personnel. After the blood had
dried, the portion of the slide with the thin smear was fixed with methanol; slides were subse-
quently stained with 3% Giemsa. Ill-appearing children also had a drop of blood tested with a
rapid diagnostic test for malaria and were referred to the local government health facility if the
test was positive. The thick smear was assessed for the presence and density of parasites and
gametocytes by 2 independent experienced laboratory workers at the Centre de Recherche
Me´dicale et Sanitaire (Niamey, Niger). Parasite density, measured in parasites per microliter,
was estimated as the ratio of asexual parasites to white blood cells after inspecting a minimum
Mass azithromycin and malaria in Niger
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of 200 white blood cells, multiplied by 8,000 (i.e., an arbitrary yet accepted convention for the
number of white blood cells per microliter). Thin smears were assessed for malaria species.
Laboratory workers were masked to treatment allocation. Discrepancies were adjudicated by
additional independent laboratory workers until a majority consensus was achieved. A consen-
sus for density measurements required a�1 log10-unit difference between the majority of
measurements; the mean density from the consensus was taken as the study measurement.
Intervention
A single, directly observed dose of study drug was administered to all eligible children approxi-
mately every 6 months. Study treatment was administered after monitoring was complete for
all children, on a different day from the monitoring visit. Field staff distributed study drug in a
single community at a time. The same smartphone-based mobile application used in the cen-
sus was also used for treatment. All children aged 1 to 59 months entered into the most recent
census were offered treatment, and children who were absent or not eligible at the time of the
previous census were entered into the mobile application and offered treatment. Azithromycin
was dosed at 20 mg/kg, calculated by weight for small children and approximated by height for
children who could stand [15]. The same volume of an identical-appearing placebo suspension
was administered in the placebo communities. Guardians were instructed to contact a village
representative if their child experienced any adverse events within 7 days of receiving study
drug; the representative then informed the study coordinator. A formal adverse event survey
was performed for children aged 1 to 5 months and is reported separately [16].
Fig 3. Timing of examination visits and treatment. The x-axis depicts calendar time during the trial, and the y-axis shows each community as a discrete row.
Examinations and treatment visits were typically conducted over a several-day period; the vertical lines represent the median date of the examination (black) or
treatment (blue for azithromycin, orange for placebo).
https://doi.org/10.1371/journal.pmed.1002835.g003
Mass azithromycin and malaria in Niger
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002835 June 25, 2019 7 / 15
Outcomes
The prespecified primary malaria outcome was the presence or absence of at least 1 parasite on
thick blood smear in children 1 to 59 months of age, assessed as a community-level prevalence.
Prespecified secondary outcomes included parasitemia density, gametocyte density, hemoglo-
bin concentration at the individual level, and presence of anemia (hemoglobin < 11 g/dL) at
the community level [17].
Statistical considerations
The MORDOR study sites in Malawi, Niger, and Tanzania conducted independent trials of
morbidity outcomes with slightly different methods and outcomes. In consultation with the
trial’s Data Safety and Monitoring Committee, we prespecified a separate analysis for each
morbidity outcome at each site (S1 Protocol). Community-level prevalence outcomes from
months 12 and 24 were modeled in a mixed-effects linear regression model that included a
fixed term for treatment arm, baseline prevalence, and date of sample collection and a random
effect for community. Individual-level outcomes from months 12 and 24 were analyzed in
mixed-effects linear or logistic regression models that included fixed effects for treatment arm
and date of sample collection and nested random effects for individuals within communities.
Square root transformations were used for the parasitemia prevalence, anemia prevalence, and
parasite density outcomes to improve the normality of residuals. Intraclass correlation coeffi-
cients (ICCs) were derived from the regression models at the level of the randomization unit.
P values were determined by Monte Carlo permutation (10,000 permutations). All analyses
were performed in an intention-to-treat fashion with the statistical software R version 3.4.0.
The trial was overseen by a Data Safety and Monitoring Committee.
Sample size
Based on previous studies in Niger, we anticipated a prevalence of malaria parasitemia in
untreated communities of 25% and an ICC of 0.056. Assuming an alpha of 0.05, enrolling 40
children in each of 15 communities per arm would provide more than 80% power to detect a
13% absolute difference between the 2 treatment arms.
Results
Baseline characteristics of the 15 azithromycin-treated communities and 15 placebo-treated
communities are shown in Table 1. Communities in the placebo group were on average larger
Table 1. Baseline characteristics of the study communities, as assessed from a population census.
Characteristic Mean (95% CI)
Placebo
N = 15
Azithromycin
N = 15
Census
No. of children 1–59 mo 202 (136–268) 113 (63–163)
Age, %
0 y 14.6% (11.9%–17.2%) 13.8% (11.3%–16.4%)
1 y 14.4% (12.3%–16.6%) 15.2% (12.4%–18.0%)
2 y 19.3% (17.5%–21.1%) 18.8% (16.0%–21.6%)
3 y 23.8% (21.4%–26.3%) 24.6% (21.7%–27.5%)
4 y 27.9% (24.1%–31.7%) 27.5% (24.3%–30.7%)
Female, % 48.0% (45.7%–50.3%) 48.2% (45.5%–50.8%)
https://doi.org/10.1371/journal.pmed.1002835.t001
Mass azithromycin and malaria in Niger
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than those in the azithromycin group, with a total of 1,695 children aged 1 to 59 months enu-
merated in the azithromycin arm and a total of 3,029 children enumerated in the placebo arm
at baseline. The age and sex distribution within communities was similar between the 2
groups. All communities received their allocated study medication, and none were lost to fol-
low-up. Across all 4 study visits, study drug was distributed to 78.7% (95% CI 74.9%–82.6%) of
eligible children in the azithromycin group and 81.7% (95% CI 78.9%–84.5%) of eligible chil-
dren in the placebo group (Fig 1).
No hospitalizations or life-threatening illnesses were reported in either group over the dura-
tion of the study. Guardians of 1- to 5-month-old children were surveyed about adverse events
approximately 1 month after treatment given the paucity of azithromycin safety data in this
population. Detailed results have been published elsewhere [16]. In summary, the most com-
mon guardian-reported adverse events were as follows: diarrhea, which was reported in 110
out of 571 (19.3%) children in the azithromycin group and 321 out of 1,141 (28.1%) children
in the placebo group (P = 0.03); vomiting, reported in 91 out of 571 (15.9%) from the azithro-
mycin group and 240 out of 1,141 (21.0%) from the placebo group (P = 0.07); and rash,
reported in 70 out of 571 (12.3%) from the azithromycin group and 155 out of 1,141 (13.6%)
from the placebo group (P = 0.07).
The prevalence of parasitemia among 1- to 59-month-old children for each community
over time is shown in Table 2 and Fig 4. At baseline, the mean prevalence of malaria parasite-
mia was 6.7% (95% CI 4.0%–12.6%) in the placebo group and 8.9% (95% CI 5.1%–15.7%) in
the azithromycin group. At month 12, the mean prevalence was 15.3% (95% CI 10.8%–20.6%)
and 8.8% (95% CI 5.1%–14.3%) in the placebo and azithromycin groups, respectively, and at
month 24, these estimates were 4.8% (3.3%–6.4%) and 3.5% (1.9%–5.5%), respectively. Parasi-
temia prevalence was significantly lower in the azithromycin group at months 12 and 24 after
adjusting for baseline parasitemia and the date of sample collection (P = 0.02; ICC = 0.26;
square-root–transformed outcome; prespecified primary outcome). If the mean malaria preva-
lence was 10% in the placebo-treated communities (i.e., the post-treatment average observed
in the present study), then azithromycin would be predicted to reduce the prevalence of
malaria parasitemia by an absolute difference of 5.3% (95% CI −1.4 to −8.0%). The conclusions
did not change in a sensitivity analysis of individual-level data (odds ratio [OR] 0.54 relative to
the placebo group, 95% CI 0.30–0.97, adjusted for date of sample collection).
The average parasite density among parasitemic children is shown for each treatment arm
in Table 3. Parasite density was lower in the azithromycin group in a mixed-effects linear
regression of the 12- and 24-month values adjusted for the date of sample collection, with den-
sity estimates 7,540 parasites/μl lower (95% CI −350 to −12,550 parasites/μl) than the placebo
arm assuming a mean parasite density in the placebo arm of 17,000 as observed in this study
(ICC = 0.02; P = 0.02; square-root–transformed outcome). No significant differences in game-
tocyte prevalence or density were observed between the 2 groups (S1 Table, S2 Table).
Mean hemoglobin measurements are summarized for each study visit and treatment arm
in Table 3. No significant difference was observed between the 2 groups after adjusting for
date of sample collection, although the azithromycin group had slightly higher hemoglobin
measurements (mean 0.34 g/dL higher than the placebo group, 95% CI −0.06 to 0.75 g/dL;
ICC = 0.09; P = 0.10). Similarly, the prevalence of anemia was not significantly different
between the 2 groups in the permutation test (P = 0.06; ICC = 0.08; square-root–transformed
outcome; S3 Table), although the regression model predicted less anemia in the azithromycin-
treated communities (absolute difference 6.7%, 95% CI −0.2 to −12.8%, assuming a 75% preva-
lence of anemia as approximately observed in the placebo-treated communities).
Mass azithromycin and malaria in Niger
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Discussion
In this placebo-controlled study, mass azithromycin distributions resulted in a significantly
lower prevalence of malaria parasitemia and lower parasite density levels when assessed at 2
annual post-treatment study visits. Hemoglobin levels were slightly greater and the prevalence
of anemia slightly lower in azithromycin-treated communities, although neither of these were
statistically significant. These results raise the possibility that reductions in malaria may in part
explain the childhood mortality benefit of azithromycin.
The prevalence of malaria parasitemia was lower in this study than in several other popula-
tion-based studies done in other parts of Niger [9, 13]. This may be explained by geographic
and year-to-year variations in malaria prevalence [18–20]. The relatively low malaria
Table 2. Community-specific prevalence of malaria parasitemia.
No. of positive out of total tested, per community (%)
Community Month 0 Month 12 Month 24
Placebo
1 0/40 (0%) 5/40 (12.5%) 4/40 (10.0%)
2 2/23 (8.7%) 4/28 (14.3%) 2/31 (6.5%)
3 0/38 (0%) 6/28 (21.4%) 0/42 (0%)
4 2/42 (4.8%) 2/41 (4.9%) 0/41 (0%)
5 11/37 (29.7%) 9/37 (24.3%) 3/41 (7.3%)
6 4/37 (10.8%) 3/36 (8.3%) 1/42 (2.4%)
7 1/22 (4.5%) 5/19 (26.3%) 1/25 (4.0%)
8 1/29 (3.4%) 8/39 (20.5%) 3/42 (7.1%)
9 1/43 (2.3%) 2/38 (5.3%) 1/44 (2.3%)
10 4/36 (11.1%) 3/40 (7.5%) 1/40 (2.5%)
11 2/40 (5.0%) 4/40 (10.0%) 3/41 (7.3%)
12 0/37 (0%) 2/40 (5.0%) 1/41 (2.4%)
13 4/41 (9.8%) 14/40 (35.0%) 2/41 (4.9%)
14 4/39 (10.3%) 12/41 (29.3%) 4/41 (9.8%)
15 0/38 (0%) 2/41 (4.9%) 2/40 (5.0%)
Mean (95% CI) 6.7% (4.0%–12.6%) 15.3% (10.8%–20.6%) 4.8% (3.3%–6.4%)
Azithromycin
16 4/40 (10.0%) 2/42 (4.8%) 4/42 (9.5%)
17 1/24 (4.2%) 9/39 (23.1%) 2/33 (6.1%)
18 1/40 (2.5%) 11/38 (28.9%) 2/40 (5.0%)
19 3/32 (9.4%) 0/28 (0%) 0/21 (0%)
20 15/39 (38.5%) 2/39 (5.1%) 0/41 (0%)
21 1/30 (3.3%) 0/42 (0%) 1/40 (2.5%)
22 0/40 (0%) 4/40 (10.0%) 4/40 (10.0%)
23 0/39 (0%) 3/39 (7.7%) 0/40 (0%)
24 0/41 (0%) 4/41 (9.8%) 3/42 (7.1%)
25 7/39 (17.9%) 8/38 (21.1%) 0/40 (0%)
26 0/26 (0%) 0/16 (0%) 1/40 (2.5%)
27 8/46 (17.4%) 1/39 (5.0%) 3/42 (7.1%)
28 2/37 (5.4%) 1/32 (3.1%) 0/23 (0%)
29 5/38 (13.2%) 1/40 (2.5%) 1/43 (2.3%)
30 5/41 (12.2%) 5/38 (13.2%) 0/40 (0%)
Mean (95% CI) 8.9% (5.1%–15.7%) 8.8% (5.1%–14.3%) 3.5% (1.9%–5.5%)
https://doi.org/10.1371/journal.pmed.1002835.t002
Mass azithromycin and malaria in Niger
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002835 June 25, 2019 10 / 15
prevalence could also be due to the timing of the annual monitoring visits, which were done in
the spring, before the major seasonal peak in the fall. The prevalence of malaria would be
expected to increase later in the summer. Indeed, the malaria estimates were higher in each
group at the month 12 assessments, which on average occurred several months later than at
the other 2 time points. The preponderance of malaria during the autumn months in Niger
was suggested by the parent MORDOR trial since the largest number of childhood deaths
occurred during this time and malaria was the most common attributed cause of death from
verbal autopsies, although it is important to note that verbal autopsy has poor diagnostic accu-
racy for malarial deaths and can lead to overestimates in areas with endemic malaria like Niger
[1, 21, 22]. The strength of the statistical association between mass azithromycin treatments
and malaria could depend on the timing of treatments as well as the timing of assessments, so
it is possible that the present trial did not maximize the chance of finding an antimalarial effect
of azithromycin. Nonetheless, our finding of reduced parasitemia in the azithromycin group
even in the presumably low-prevalence spring months is consistent with azithromycin exerting
a sustained reduction in malarial burden throughout the year.
Fig 4. Community-specific malaria parasitemia prevalence among 1- to 59-month-old children at the 3 annual
monitoring visits. Each thin line represents a community, and the thick lines represent the mean prevalence of
parasitemia in each trial arm.
https://doi.org/10.1371/journal.pmed.1002835.g004
Table 3. Individual-level parasite density and hemoglobin.
Parasite density, parasites/μl� Hemoglobin, g/dL
Placebo Azithromycin Placebo Azithromycin
Month N Mean (95% CI) N Mean (95% CI) N Mean (95% CI) N Mean (95% CI)
0 36 550 (250–1,200) 52 70,020 (600–225,890) 542 9.7 (9.5–10.0) 552 9.8 (9.5–10.0)
12 81 22,470 (4,390–56,360) 51 400 (250–760) 548 9.1 (8.7–9.5) 551 9.7 (9.2–10.2)
24 28 740 (150–2,370) 21 640 (130–1,535) 592 10.1 (9.9–10.3) 567 10.2 (9.9–10.4)
�Among parasitemic children; rounded to nearest 10.
Values represent individual-level means with bootstrapped 95% CIs resampled at the community level.
https://doi.org/10.1371/journal.pmed.1002835.t003
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The present study is consistent with several previous studies that have assessed the antima-
larial activity of azithromycin. As is the case with some other antibiotics, azithromycin acts
against the parasite apicoplast and exerts slow antimalarial activity [6]. In clinical trials, azi-
thromycin has been found to improve the treatment efficacy of both artesunate and chloro-
quine relative to each agent alone [4, 5, 11]. Azithromycin has also been shown to prevent
malaria infections, although its efficacy appears to be inferior to that of doxycycline [2, 3].
Malaria outcomes have been measured during studies of mass azithromycin distributions for
trachoma, with reductions in malaria parasitemia observed in some studies but not in others
[9, 13, 23, 24]. The present study improved upon previous studies of mass azithromycin distri-
bution in that it was placebo controlled and enforced strict masking procedures both in the
field and by laboratory staff.
The public health impact of MORDOR remains to be seen. The mortality benefit of mass
azithromycin distributions was especially strong for the youngest children and for the Niger
site, so it may ultimately make sense to target antibiotic distributions to those most likely to
benefit. Doing so would have the added benefit of reducing the total volume of antibiotics dis-
tributed, which may limit antimicrobial resistance. Studies like this one may help elucidate
where to target antibiotics. Namely, our results suggest that mass azithromycin distributions
might be more effective in reducing mortality in places with prevalent malaria. Subsequent
studies assessing the impact of mass azithromycin on other common causes of childhood mor-
tality will be important, as will studies in areas without prevalent malaria. For example, if the
mortality benefit of mass azithromycin is mediated only through malaria reduction, then sea-
sonal malaria chemoprevention might be a more efficient way to prevent childhood mortality.
In fact, a recent household-randomized trial found that adding azithromycin to seasonal
malaria chemoprevention did not provide a benefit for malaria or mortality, perhaps because
any antimalarial effect of azithromycin was reduced when given along with the more effective
antimalarial drugs [25]. However, that same study also found that azithromycin treatment was
associated with reductions in diarrheal and respiratory infections. If other studies confirm
these associations, wider implementation of mass azithromycin distributions may be
warranted.
Although the most likely explanation for the observed result is a direct effect of azithromy-
cin on those children who took the drug, it is important to note that mass antibiotics may also
have indirect spillover effects [14]. By reducing the overall burden of parasitemia, mass azi-
thromycin distributions reduced the reservoir of parasites in the community, which may have
supplemented any direct effect of the antibiotic.
The present trial has several limitations. Study drug was generally administered in the dry
seasons. Although mathematical models have suggested that this may in fact be the optimal
time to reduce the community burden of malaria, the ideal time to administer antibiotics
remains unclear [26]. Likewise, due to logistical reasons, monitoring visits were conducted in
the dry season, which may not provide a complete picture of the impact of the intervention
during the peak malaria transmission season. Grading of thick smears is inherently subjective,
although the possibility of misclassification error was mitigated by having at least 2 indepen-
dent laboratory staff assess each slide. Finally, the generalizability of the results outside Niger
remains unclear, and even the generalizability within Niger is not assured given considerable
variation in malaria transmission within the country [18–20]. The other 2 MORDOR sites in
Malawi and Tanzania had a lower reduction of mortality in subgroup analyses, and thus the
malaria results for these sites will provide important context for the interpretation of the pres-
ent report and may ultimately alter our understanding of the causal relationship between mass
azithromycin, malaria, and mortality.
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In conclusion, a placebo-controlled, cluster-randomized trial found that biannual mass azi-
thromycin distributions targeted to preschool children in Niger resulted in a reduction in
malaria parasitemia in 1- to 59-month-old children. Study communities were selected from
the same set of communities and treated with the same intervention as the parent MORDOR
trial, so results of this study can be extrapolated to the larger trial. As such, this study suggests
that the mortality benefits conveyed by mass azithromycin distributions may have been in part
due to the antimalarial activity of azithromycin. Similar trials performed in other settings will
be important to confirm the association found in this trial.
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